IP Library › Granted Patent US 12,403,161
Granted Patent B2
US 12,403,161 · App. 16/973,688 · Granted Sep 2, 2025

Compositions for drug delivery and methods of use thereof

Inventors: Jonathan N. Thon (Watertown, MA); Brad Dykstra (Watertown, MA); Brenden William Smith (Watertown, MA)
Assignee: Stellular Bio, Inc.
A61K35/19A61K9/127A61K9/1271A61K47/6901C12N5/0607C12N5/0644C12N5/0696C12N2501/115C12N2501/125C12N2501/145C12N2501/155C12N2501/165C12N2501/2303C12N2501/2306C12N2501/26C12N2501/415C12N2501/91C12N2506/03C12N2506/45C12N2513/00C12N2533/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,403,161
App. No.
16/973,688
Granted
Sep 2, 2025
Kind
B2
Abstract

Methods for producing megakaryocytes and platelets derived from inducible pluripotent stem cells and comprising a therapeutic agent are provided. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.

Claims (30)

1. A method for differentiating induced pluripotent stem cells (iPSC) to prepare a composition, the method comprising:

expanding induced pluripotent cells in a matrix independent culture using single cell passaging;

dissociating the expanded pluripotent cells into a single cell suspension;

differentiating the dissociated pluripotent cells in a first culture medium into hemogenic endothelial cells;

differentiating the hemogenic endothelial cells in a second culture medium into megakaryocytic progenitors;

differentiating the megakaryocytic progenitors in a third culture medium into megakaryocytes; and

lysing the megakaryocytes so as to obtain a lysate composition comprising one or more of Interleukin 1-beta, Interleukin 16, Interleukin 12P40, TNF-beta, BCA-1, IP-30, Fractalkine, GCkine, MCP-4, MIP-1alpha, MIP-1beta, SDF-1alpha, SDF-1beta, or a combination thereof.

2. The method of claim 1 , wherein the megakaryocytes are CD42b + , CD61 + , and DNA + .

3. The method of claim 1 , wherein the first culture medium comprises one or more of Bone morphogenic protein 4 (BMP4), Basic fibroblast growth factor (bFGF), and Vascular endothelial growth factor (VEGF).

4. The method of claim 1 , wherein the first culture medium comprises BMP4 for a first time period, and for a second time period bFGF and VEGF are added to the first culture medium.

5. The method of claim 4 , wherein for the first time period, the first culture medium comprises BMP4 without bFGF and VEGF.

6. The method of claim 1 , wherein the second culture medium comprises one or more of Stem cell factor (SCF), Thrombopoietin (TPO), Fms-related tyrosine kinase 3 ligand (Flt3-L), Interleukin-3 (IL-3), Interleukin-6 (IL-6) and Heparin.

7. The method of claim 1 , wherein the third culture medium comprises one or more of Stem cell factor (SCF), Thrombopoietin (TPO), Interleukin-6 (IL-6), Interleukin-9 (IL-9) and Heparin.

8. The method of claim 1 , wherein one or more of the dissociated pluripotent cells, the hemogenic endothelial cells or the megakaryocytic progenitors are differentiated under continuous agitation in a matrix independent culture.

9. The method of claim 1 , wherein the dissociated pluripotent cells are cultured so as to form self-aggregating pluripotent cell spheroids in a matrix independent culture.

10. The method of claim 9 , wherein the self-aggregating pluripotent cell spheroids are differentiated so as to form hemogenic endothelial cell spheroids.

11. The method of claim 10 , wherein the hemogenic endothelial cell spheroids are differentiated so as to produce the megakaryocytic progenitors, causing the hemogenic endothelial cell spheroids to release the megakaryocytic progenitors into suspension while maintaining the hemogenic endothelial cell spheroids for subsequent production and release of the megakaryocytic progenitors.

12. A method for differentiating induced pluripotent stem cells (iPSC) to prepare a composition, the method comprising:

differentiating induced pluripotent cells in a first culture medium into hemogenic endothelial cells, the first culture medium comprising BMP4 for a first time period and bFGF and VEGF for a second time period after the first time period;

differentiating the hemogenic endothelial cells in a second culture medium into megakaryocytic progenitors;

differentiating the megakaryocytic progenitors in a third culture medium into megakaryocytes; and

lysing the megakaryocytes so as to obtain a lysate composition comprising one or more of Interleukin 1-beta, Interleukin 16, Interleukin 12P40, TNF-beta, BCA-1, IP-30, Fractalkine, GCkine, MCP-4, MIP-1alpha, MIP-1beta, SDF-1alpha, SDF-1beta, or a combination thereof.

13. The method of claim 12 , wherein for the first time period, the first culture medium comprises BMP4 without bFGF and VEGF.

14. The method of claim 12 , wherein the second culture medium comprises one or more of Stem cell factor (SCF), Thrombopoietin (TPO), Fms-related tyrosine kinase 3 ligand (Flt3-L), Interleukin-3 (IL-3), Interleukin-6 (IL-6) and Heparin.

15. The method of claim 12 , wherein the third culture medium comprises one or more of Stem cell factor (SCF), Thrombopoietin (TPO), Interleukin-6 (IL-6), Interleukin-9 (IL-9) and Heparin.

16. The method of claim 12 , wherein differentiating the induced pluripotent cells comprises expanding induced pluripotent cells in a matrix independent culture using single cell passaging and dissociating the expanded pluripotent cells into a single cell suspension.

17. The method of claim 12 , wherein one or more of the induced pluripotent cells, the hemogenic endothelial cells or the megakaryocytic progenitors are differentiated under continuous agitation.

18. The method of claim 12 , wherein the induced pluripotent cells are cultured so as to form self-aggregating pluripotent cell spheroids.

19. The method of claim 18 , wherein the self-aggregating pluripotent cell spheroids are differentiated so as to form hemogenic endothelial cell spheroids.

20. The method of claim 19 , wherein the hemogenic endothelial cell spheroids are differentiated so as to produce the megakaryocytic progenitors, causing the hemogenic endothelial cell spheroids to release the megakaryocytic progenitors into suspension while maintaining the hemogenic endothelial cell spheroids for subsequent production and release of the megakaryocytic progenitors.

Assignments (2)
CHANGE OF NAME Recorded Mar 17, 2023
From: PLATELET BIOGENESIS, INC.
To: STELLULAR BIO, INC.
Reel/Frame 063116/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2021
From: THON, JONATHAN N.; DYKSTRA, BRAD; SMITH, BRENDEN WILLIAM
To: PLATELET BIOGENESIS, INC.
Reel/Frame 055972/0938 →
Continuity (2)
Provisional Application 62692277 · Jun 29, 2018
Related Publication 20210252070A1 · Aug 19, 2021
References Cited (215)
US 5292524A · Male et al. · 1994 [cited by applicant]
US 5521290A · Sivam et al. · 1996 [cited by applicant]
US 5605689A · Ammann · 1997 [cited by applicant]
US 5733254A · Jones et al. · 1998 [cited by applicant]
US 5811301A · Cameron · 1998 [cited by applicant]
US 6225119B1 · Qasba et al. · 2001 [cited by applicant]
US 6589759B1 · Loscalzo et al. · 2003 [cited by applicant]
US 6723497B2 · Wolkers et al. · 2004 [cited by applicant]
US 7494807B2 · Nakorn et al. · 2009 [cited by applicant]
US 7794707B2 · Penninger et al. · 2010 [cited by applicant]
US 7939063B2 · Cines et al. · 2011 [cited by applicant]
US 8137970B2 · Jhon et al. · 2012 [cited by applicant]
US 8263556B2 · Du Clos et al. · 2012 [cited by applicant]
US 8372642B2 · Rajesh et al. · 2013 [cited by applicant]
US 8535943B2 · Nakano et al. · 2013 [cited by applicant]
US 8546141B2 · Nakauchi et al. · 2013 [cited by applicant]
US 8557580B2 · Daigh et al. · 2013 [cited by applicant]
US 8741905B2 · Wagner et al. · 2014 [cited by applicant]
US 8835163B2 · Zhao et al. · 2014 [cited by applicant]
US 8889645B2 · Layzer et al. · 2014 [cited by applicant]
US 9012221B2 · Baruch et al. · 2015 [cited by applicant]
US 9200254B2 · Eto et al. · 2015 [cited by applicant]
US 9259443B2 · Poncz et al. · 2016 [cited by applicant]
US 9574178B2 · Mitchell et al. · 2017 [cited by applicant]
US 9574179B2 · Yu et al. · 2017 [cited by applicant]
US 9738906B2 · Eto et al. · 2017 [cited by applicant]
US 9763984B2 · Feng et al. · 2017 [cited by applicant]
US 9795965B2 · Italiano et al. · 2017 [cited by applicant]
US 9803164B2 · Mitchell · 2017 [cited by applicant]
US 9909102B2 · Baruch et al. · 2018 [cited by applicant]
US 9982034B2 · Wilcox et al. · 2018 [cited by applicant]
US 9988602B2 · Lanza et al. · 2018 [cited by applicant]
US 9988603B2 · Li et al. · 2018 [cited by applicant]
US 9993503B2 · Feng et al. · 2018 [cited by applicant]
US 10100282B2 · Rajesh et al. · 2018 [cited by applicant]
US 10294291B2 · Wilcox et al. · 2019 [cited by applicant]
US 10307462B2 · Ben Yehuda et al. · 2019 [cited by applicant]
US 10426799B2 · Feng et al. · 2019 [cited by applicant]
US 10538738B2 · Papoutsakis et al. · 2020 [cited by applicant]
US 10604738B2 · Pedersen et al. · 2020 [cited by applicant]
US 10669529B2 · Nakahata et al. · 2020 [cited by applicant]
US 10729730B2 · Zhao · 2020 [cited by applicant]
US 10869898B2 · Mata-Fink et al. · 2020 [cited by applicant]
US 10894065B2 · Feng et al. · 2021 [cited by applicant]
US 12060576B2 · Thon · 2024 [cited by examiner]
US 20020009500A1 · Wolkers et al. · 2002 [cited by applicant]
US 20020141992A1 · Nieswandt · 2002 [cited by applicant]
US 20020176804A1 · Strand et al. · 2002 [cited by applicant]
US 20050074426A1 · Corti et al. · 2005 [cited by applicant]
US 20050086710A1 · Peluso et al. · 2005 [cited by applicant]
US 20050252892A1 · Newman et al. · 2005 [cited by applicant]
US 20060099198A1 · Thomson et al. · 2006 [cited by applicant]
US 20060153813A1 · Quesenberry · 2006 [cited by applicant]
US 20070077246A1 · Koenig et al. · 2007 [cited by applicant]
US 20070077654A1 · Thomson et al. · 2007 [cited by applicant]
US 20070141656A1 · Mapes et al. · 2007 [cited by applicant]
US 20070243608A1 · Kyba et al. · 2007 [cited by applicant]
US 20080268535A1 · Jhon et al. · 2008 [cited by applicant]
US 20090232834A1 · Al-Harbi et al. · 2009 [cited by applicant]
US 20100063070A1 · Raud · 2010 [cited by applicant]
US 20100248361A1 · Lasky et al. · 2010 [cited by applicant]
US 20110039333A1 · Kahn et al. · 2011 [cited by applicant]
US 20110086424A1 · Lanza et al. · 2011 [cited by applicant]
US 20110243813A1 · Jackinsky et al. · 2011 [cited by applicant]
US 20120238020A1 · Mitchell et al. · 2012 [cited by applicant]
US 20120282228A1 · Bhasin · 2012 [cited by applicant]
US 20120301438A1 · Cheng · 2012 [cited by applicant]
US 20120315338A1 · Li et al. · 2012 [cited by applicant]
US 20130052662A1 · Barnes et al. · 2013 [cited by applicant]
US 20130061961A1 · Rapp et al. · 2013 [cited by applicant]
US 20130210141A1 · Rajesh et al. · 2013 [cited by applicant]
US 20140037600A1 · Yu et al. · 2014 [cited by applicant]
US 20140099359A1 · SenGupta et al. · 2014 [cited by applicant]
US 20140127815A1 · Eto et al. · 2014 [cited by applicant]
US 20140205582A1 · Karsunky et al. · 2014 [cited by applicant]
US 20140227780A1 · Nishino et al. · 2014 [cited by applicant]
US 20140271590A1 · Feng et al. · 2014 [cited by applicant]
US 20140273211A1 · Slukvin et al. · 2014 [cited by applicant]
US 20150111296A1 · Pedersen et al. · 2015 [cited by applicant]
US 20150203819A1 · Murphy et al. · 2015 [cited by applicant]
US 20150275176A1 · Kobayashi et al. · 2015 [cited by applicant]
US 20150313944A1 · Feng et al. · 2015 [cited by applicant]
US 20150335682A1 · Murphy et al. · 2015 [cited by applicant]
US 20150361453A1 · Gresele et al. · 2015 [cited by applicant]
US 20160002586A1 · Mitchell · 2016 [cited by applicant]
US 20160002599A1 · Eto · 2016 [cited by applicant]
US 20160022736A1 · Feng · 2016 [cited by examiner]
US 20160139124A1 · Newman et al. · 2016 [cited by applicant]
US 20160168540A1 · Hirata et al. · 2016 [cited by applicant]
US 20160177265A1 · Matsubara et al. · 2016 [cited by applicant]
US 20160209331A1 · Babic et al. · 2016 [cited by applicant]
US 20160272941A1 · Baruch et al. · 2016 [cited by applicant]
US 20160324897A1 · Ingber et al. · 2016 [cited by applicant]
US 20170121682A1 · Mitchell et al. · 2017 [cited by applicant]
US 20170130195A1 · Im et al. · 2017 [cited by applicant]
US 20170183616A1 · Thon et al. · 2017 [cited by applicant]
US 20180016597A1 · Eto et al. · 2018 [cited by applicant]
US 20180030415A1 · Nguyen et al. · 2018 [cited by applicant]
US 20180044634A1 · Dohda et al. · 2018 [cited by applicant]
US 20180055891A1 · Zhao · 2018 [cited by applicant]
US 20180135020A1 · Zhao · 2018 [cited by applicant]
US 20180161379A1 · Peterson et al. · 2018 [cited by applicant]
US 20180201889A1 · Sharei et al. · 2018 [cited by applicant]
US 20180237797A1 · Loh · 2018 [cited by applicant]
US 20180258395A1 · Shigemori et al. · 2018 [cited by applicant]
US 20180282697A1 · Hirose et al. · 2018 [cited by applicant]
US 20180318352A1 · Shigemori et al. · 2018 [cited by applicant]
US 20180318353A1 · Feng et al. · 2018 [cited by applicant]
US 20180334652A1 · Thon · 2018 [cited by applicant]
US 20190032015A1 · Eto et al. · 2019 [cited by applicant]
US 20190048317A1 · Eto et al. · 2019 [cited by applicant]
US 20190144823A1 · Slukvin et al. · 2019 [cited by applicant]
US 20190160103A1 · Garbin · 2019 [cited by applicant]
US 20190169566A1 · Gevaert et al. · 2019 [cited by applicant]
US 20190269732A1 · Matsubara et al. · 2019 [cited by applicant]
US 20190290686A1 · Wickham et al. · 2019 [cited by applicant]
US 20190290696A1 · DeMiroschedji · 2019 [cited by applicant]
US 20190376034A1 · Kahvejian et al. · 2019 [cited by applicant]
US 20200010809A1 · Wamhoff et al. · 2020 [cited by applicant]
US 20200017812A1 · Thon · 2020 [cited by applicant]
US 20200023011A1 · Feng et al. · 2020 [cited by applicant]
US 20200138868A1 · Thon et al. · 2020 [cited by applicant]
US 20200255804A1 · Pedersen et al. · 2020 [cited by applicant]
US 20210000750A1 · Gu et al. · 2021 [cited by applicant]
US 20210054336A1 · Thon · 2021 [cited by examiner]
US 20210299180A1 · Hett et al. · 2021 [cited by applicant]
US 20210299181A1 · Hett et al. · 2021 [cited by applicant]
US 20210371824A1 · Blasczyk · 2021 [cited by examiner]
US 20220143095A1 · Hett et al. · 2022 [cited by applicant]
US 20230174939A1 · Falb et al. · 2023 [cited by applicant]
US 20230183646A1 · Peters et al. · 2023 [cited by applicant]
US 20250027046A1 · Thon et al. · 2025 [cited by applicant]
WO 2006050330A1 · 2006 [cited by applicant]
WO 2008121027A1 · 2008 [cited by applicant]
WO 2009002811A1 · 2008 [cited by applicant]
WO 2009137629A1 · 2009 [cited by applicant]
WO 2010099539A1 · 2010 [cited by applicant]
WO 2012112690A2 · 2012 [cited by applicant]
WO 2014100779A1 · 2014 [cited by applicant]
WO 2014138485A1 · 2014 [cited by applicant]
WO 2015179301A1 · 2015 [cited by applicant]
WO 2016141137A1 · 2016 [cited by applicant]
WO 2016160860A1 · 2016 [cited by applicant]
WO 2017013262A1 · 2017 [cited by applicant]
WO 2017070337A1 · 2017 [cited by applicant]
WO 2017211906A1 · 2017 [cited by applicant]
WO 2018053010A1 · 2018 [cited by applicant]
WO 2018164040A1 · 2018 [cited by applicant]
WO 2018165308A1 · 2018 [cited by applicant]
WO 2018202881A1 · 2018 [cited by applicant]
WO WO2018202900A1 · 2018 [cited by examiner]
WO 2018227286A1 · 2018 [cited by applicant]
WO 2019009364A1 · 2019 [cited by applicant]
WO 2019028192A1 · 2019 [cited by applicant]
WO 2019089826A1 · 2019 [cited by applicant]
WO 2019094614A1 · 2019 [cited by applicant]
WO 2019126818A1 · 2019 [cited by applicant]
WO 2019136318A1 · 2019 [cited by applicant]
WO 2019136318A2 · 2019 [cited by applicant]
WO 2019161192A1 · 2019 [cited by applicant]
WO 2020006539A1 · 2020 [cited by applicant]
WO 2020014175A1 · 2020 [cited by applicant]
WO 2021195496A2 · 2021 [cited by applicant]
WO 2021231990A2 · 2021 [cited by applicant]
Eicke et al. Transfus Med Hemother 2017;44 (suppl 1):2-87, V03-2. (Year: 2017). [cited by examiner]
Baigger, J Cell Mol Med. Sep. 22, 2018, 22(9), 4545-4549, Electronic Publication Date: Jun. 12, 2018. (Year: 2018). [cited by examiner]
Aatonen et al., “Isolation and Characterization of Platelet-Derived Extracellular Vesicles”, Journal of Extracellular Vesicles, vol. 3, No. 1, p. 24692, Jan. 1, 2013. [cited by applicant]
Alshehri et al., “Fibrin Activates GPVI in Human and Mouse Platelets”, Blood, vol. 126, No. 13, pp. 1601-1608, Sep. 24, 2015. [cited by applicant]
Hansen et al., “Human-Induced Pluripotent Stem Cell-Derived Blood Products: State of the Art and Future Directions”, FEBS Letters, vol. 593, pp. 3288-3303, 2019. [cited by applicant]
Ito et al., “Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production”, Cell, vol. 174, No. 3, pp. 636-648, Jul. 26, 2018. [cited by applicant]
Orban et al., “Functional Comparison of Induced Pluripotent Stem Cell- and Blood-Derived GPIIbIIIa Deficient Platelets”, PLoS One, vol. 20, No. 1, p. e0115978, Jan. 21, 2015. [cited by applicant]
Sullenbarger et al., “Prolonged Continuos in Vitro Human Platelet Production Using Three-Dimensional Scaffolds”, Experimental Hematology, vol. 37, No. 1, pp. 101-110, Jan. 1, 2009. [cited by applicant]
Preliminary Rejection Report (South Korea); Dated: Sep. 22, 2022. [cited by applicant]
Title: “Progress and challenges in large-scale expansion of human pluripotent stem cells”; By: Christina Kropp; Dated: Oct. 25, 2016. [cited by applicant]
Title: “Application of small molecule CHIR99021 leads to the loss of hemangioblast progenitor and increased hematopoiesis of human pluripotent stem cells”; By: Yekaterina Galat; Date: May 29, 2018. [cited by applicant]
Dege et al., “Directed Differentiation of Primitive and Definitive Hematopoietic Progenitors from Human Pluripotent Stem Cells,” Journal of Visualized Experiments, Nov. 1, 2017, vol. 129, e55196, pp. 1-9. [cited by applicant]
Fujimoto et al., “Production of functional platelets by differentiated embryonic stem (ES) cells in vitro,” Blood, Dec. 1, 2003, vol. 102, No. 12, pp. 4044-4051. [cited by applicant]
Galat et al., “Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential,” Stem Cell Research & Therapy, Mar. 17, 2017, vol. 8, Article No.… [cited by applicant]
Hong et al., “Transfection of Human Platelets with Short Interfering RNA,” Clinical and Translational Science, Jun. 27, 2011, vol. 4, Iss. 3, pp. 180-182. [cited by applicant]
Khan, Kishwar Hayat, “Gene Transfer Technologies and their Applications: Roles in Human Diseases,” Asian Journal of Experimental Biological Science, 2010, vol. 1, Iss. 1, pp. 208-218. [cited by applicant]
Mangin et al., “Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRγ deficiency,” Blood, Jun. 1, 2006, vol. 107, No. 11, pp. 4346-4353. [cited by applicant]
Ohmori et al., “Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibα promoter: in vivo model for platelet-targeting gene therapy,” The FASEB Journa… [cited by applicant]
Pascreau et al., “Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies,” Journal of Thrombosis and Haemostasis, Jul. 4, 2019, vol. 17, Iss. 11, … [cited by applicant]
Tozawa et al., “Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line,” Blood, Feb. 14, 2019, vol. 133, No. 7, pp. 633-643. [cited by applicant]
Wang et al., “Scalable Production of Human Erythrocytes from Induced Pluripotent Stem Cells,” bioRxiv, Apr. 23, 2016, pp. 1-31. [cited by applicant]
Wells, D. J., “Gene Therapy Progress and Prospects: Electroporation and other physical methods,” Gene Therapy, Aug. 5, 2004, vol. 11, pp. 1363-1369. [cited by applicant]
Wilhelm et al., “Analysis of nanoparticle delivery to tumours,” Nature Reviews Materials, May 2016, vol. 1, Article No. 16014, pp. 1-12. [cited by applicant]
International Search Report in corresponding International Patent Application No. PCT/US19/40021, mailed Sep. 10, 2019 (4 pages). [cited by applicant]
Eisenstein et al., “Nature Biotechnology's Academic Spinouts of 2019”, Nature Biotechnology, vol. 38, pp. 546-558, May 2020. [cited by applicant]
Andrade et al., “Biotech-Educated Platelets: Beyond Tissue Regeneration 2.0,” International Journal of Molecular Sciences, vol. 21, Iss. 17, Article No. 6061, pp. 1-14, Aug. 23, 2020. [cited by applicant]
Escolar et al., “Modifications in Accessibility of Membrane Glycoproteins, Binding of Specific Ligands and Coagulation Factor V During the Activation of Platelets in Blood Emerging from Bleeding Time Wounds”, American J… [cited by applicant]
Fujiyama et al., “Development of an Ex Vivo Xenogeneic Bone Environment Producing Human Platelet-Like Cells,” PLoS One, vol. 15, No. 4, e0230507, pp. 1-12, Apr. 7, 2020. [cited by applicant]
Kailashiya et al., “Engineered Human Platelet-Derived Microparticles as Natural Vectors for Targeted Drug Delivery” Oncotarget, vol. 10, No. 56, pp. 5835-5846 (2019). [cited by applicant]
Pick et al., “Generation of Megakaryocytic Progenitors from Human Embryonic Stem Cells in a Feeder and Serum-Free Medium” PLOS One, vol. 8, No. 2, pp. 1-11, Feb. 2013. [cited by applicant]
Thon et al., “Platelet Bioreactor: Accelerated Evolution of Design and Manufacture” Platelets, vol. 28, No. 5, pp. 472-477. [cited by applicant]
Zaldivia et al., “Platelet-Derived Microvesicles in Cardiovascular Diseases” Frontiers in Cardiovascular Medicine, vol. 4, Article 74, pp. 1-13, Nov. 2017. [cited by applicant]
Amit et al., “Dynamic Suspension Culture for Scalable Expansion of Undifferentiated Human Pluripotent Stem Cells,” Nature Protocols, vol. 6, No. 5., pp. 572-579, Apr. 2011. [cited by applicant]
Everts, “Autologous Platelet-Rich Plasma and Mesenchymal Stem Cells for the Treatment of Chronic Wounds” pp. 149-180. IntechOpen, Nov. 5, 2018. [cited by applicant]
Feng et al., “Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells,” Stem Cell Reports, vol. 3, No. 5, pp. 817-831, Nov. 11, 2014. [cited by applicant]
Lam et al. “Improved human pluripotentstem cell attachment and spreading on xeno-free laminin-521-coated microcarriers results in efficient growth in agitated cultures,” BioResearch open access, vol. 4, No. 1, pp. 242-2… [cited by applicant]
Macauley et al.,“Canonical Wnt Signaling in Megakaryocytes Regulates Proplatelet Formation,” Blood, vol. 121, No. 1, pp. 188-196, Jan. 3, 2013. [cited by applicant]
Mariani et al. “Platelet Concentrates in Musculoskeletal Medicine” International Journal of Molecular Sciences, vol. 21, No. 4, pp. 1-43, Feb. 16, 2020. [cited by applicant]
Moreau et al. “Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming,” Nature Communications, vol. 7, No. 1, p. 11208, Apr. 7, 2016. [cited by applicant]
Baigger et al., “Large-Scale Production of Induced Pluripotent Stem Cells-Derived Megakaryocytes in Bioreactors” Transfus. Med. Hemother. Vol. 44, Supplement 1, pp. 5-6, Article No. V03-2, 2017. [cited by applicant]
Baigger et al., “Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application” Transfus. Med. Hemother. vol. 44, pp. 165-173, 2017. [cited by applicant]
Borger et al., “Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival under Refractoriness Conditions” Mol. Med. vol. 22, pp. 274-285, 2016. [cited by applicant]
Hirata et al., “Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ib[alpha] Retention During Expertech Vivo Generation of Human Induced Pluripotent Stem Cell-Derived Platelets” Stem Cells Translational Me… [cited by applicant]
Kronke et al., “Lenalidomide Induces Ubiquitination and Degradation of CK1a in del(5q) MDS” Nature, vol. 523, No. 7559, pp. 183-188, Jul. 1, 2015. [cited by applicant]
Lambert et al., “Challenges and Promises for the Development of Donor-Independent Platelet Transfusions” Blood, American Society of Hematology, US, vol. 121, No. 17, pp. 3319-3324, Jan. 15, 2013. [cited by applicant]
Liu et al., “Efficient Generation of Megakaryocytes from Human Induced Pluripotent Stem Cells Using Food and Drug Administration-Approved Pharmacological Reagents” Stem Cells Translational Medicine, vol. 4, No. 4, pp. 3… [cited by applicant]
Sarkar et al., “Drug Delivery Using Platelet Cancer Cell Interaction” Pharmaceutical Research, vol. 30, No. 11, pp. 2785-2794, Jun. 6, 2013. [cited by applicant]
Solomon et al., “Current Perspectives on the Use of Ancillary Materials for the Manufacture of Cellular Therapies” Cytotherapy, vol. 18, Iss. 1, pp. 1-12, Jan. 31, 2016. [cited by applicant]
Sullivan et al., “High-Level Transgene Expression in Induced Pluripotent Stem Cell-Derived Megakaryocytes: Correction of Glanzmann Thrombasthenia” Blood, vol. 123, No. 5, pp. 753-757, 2014. [cited by applicant]
International Search Report in International Application No. PCT/US2019/040021 mailed Sep. 10, 2019. [cited by applicant]
Freshney, “Culture Vessels and Substrates” Chapter 7 In Culture of Animal Cells, pp. 89-98, 2010. [cited by applicant]